Developer docs
API playgroundTry for free, no card

Search company profiles

Transcripta Bio

Full company profile

uuid0000bgp

Namestring
Transcripta Bio
Legal namestring
Transcripta Bio, Inc.
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Transcripta Bio is a privately held, Palo Alto-based biotechnology company building a transcriptome-first drug discovery platform. Its core offering combines a proprietary high-throughput RNA-Seq screening lab (the Discovery Platform), a large proprietary database mapping molecular structure and drug action to whole-cell transcriptomes (the Drug-Gene Atlas, built from over 200 million lab experiments in two years), and a proprietary AI modeling suite called Conductor AI that predicts gene expression directly from the molecular structure of uncharacterized compounds and virtually screens billions of candidates. The platform operates as a closed-loop system: wet-lab results feed the AI, AI predictions are validated in the lab, and the cycle repeats to advance multiple drug programs in parallel. The company focuses on indications where human genetics unequivocally establishes disease causality, and it has reported moving five FDA-approved drugs into single-patient studies for new indications in under two years — a process it characterizes as compressing timelines that would normally take five to eight years.

Transcripta Bio generates revenue through drug discovery partnerships with biopharma companies (structured as licensing and royalty arrangements), supplemented by data monetization via its CRISPR interference dataset distributed through Verily's (Alphabet) Pre precision health platform. Customer segments are primarily biopharma enterprise partners and patient foundations, with academic and clinical researchers reached indirectly via the Verily channel. The company is founder-led (CEO/CSO Chris Moxham, PhD, with Elizabeth Iorns as Scientific Founder & Advisor), venture-backed by JAZZ Venture Partners and BlueYard Capital plus family offices, recognized on the TIME100 Most Influential Companies 2024 list, and headquartered in Palo Alto, California with 11-50 employees.

Short descriptiontext

Transcripta Bio is a Palo Alto-based biotech using a proprietary Drug-Gene Atlas and Conductor AI to discover and repurpose drugs at transcriptome scale, partnering with biopharma companies, research centers, and patient foundations targeting genetically validated diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, transcriptome analysis, RNA-Seq screening, drug-gene mapping, biotech platform
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery Partnerships
TypeLicensing Royalties
Description

Transcripta Bio enters into partnerships with biopharma companies to discover and develop new therapies. The company leverages its platform to identify therapeutic candidates that rebalance gene expression, advancing drug candidates through development in collaboration with partners.

news.transcriptabio.com
2Data Licensing
TypeData Monetisation
Description

Transcripta provides CRISPR interference datasets through Verily's Pre platform, enabling researchers to access transcriptomic data for drug discovery research purposes.

news.transcriptabio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Conductor AI
Description

Proprietary AI modeling suite that predicts gene expression directly from molecular structure of compounds, trained on Transcripta's Drug-Gene Atlas dataset.

news.transcriptabio.com
+1 more record
Core offering1 text field

Transcripta Bio operates an integrated AI-powered drug discovery platform that combines high-throughput RNA-Seq wet-lab screening with a proprietary AI modeling suite (Conductor AI) trained on a proprietary transcriptome database (Drug-Gene Atlas). The platform maps molecular structure to whole-cell gene expression to identify therapeutic candidates that rebalance gene expression, with focus on diseases where genetic causality is established.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduced drug discovery timelines from years/months to months/weeks
+3 more records
Product overview1 text field

Transcripta Bio is a platform drug development biotechnology company offering an integrated drug discovery ecosystem consisting of the Drug-Gene Atlas (a proprietary transcriptome database), the Discovery Platform (high-throughput RNA-Seq screening), and Conductor AI (predictive modeling suite). These three components work together in a closed-loop system: wet lab results from the Discovery Platform feed into Conductor AI, which virtually screens billions of compounds to predict therapeutic candidates, with findings validated back in the lab. The platform focuses on diseases where causality is established by human genetics, using small molecules to rebalance gene expression.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-18
Description

Transcripta Bio provides CRISPR interference dataset mapping gene knockdowns linked to rare diseases as part of Verily's Pre precision health platform. This integration enables researchers to access Transcripta's transcriptomic data through Verily's self-serve platform.

2Leading Biopharma Companies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Transcripta Bio is partnering with leading biopharma companies to uncover and advance new drug discovery opportunities, leveraging the company's transcriptome-based AI platform and Drug-Gene Atlas database.

news.transcriptabio.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Transcripta Bio partners with research centers to advance drug discovery using their high-throughput screening platform and AI capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Transcripta Bio partners with patient foundations to uncover and advance new therapeutic opportunities, with particular focus on rare diseases where genetic causality is established.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning. Recursion operates a similar 'closed-loop' model and is a leading direct competitor in the AI-enabled small molecule discovery space.

TypeDirect peer
Description

Machine learning-driven drug discovery platform using high-throughput biology and proprietary data generation. Insitro is a direct competitor pursuing AI-enabled small molecule discovery with biopharma partnerships.

TypeDirect peer
Description

Computational chemistry and molecular simulation platform used for drug discovery across biopharma. Schrödinger is a direct competitor offering AI/ML-driven virtual screening and small molecule design tools.

TypeDirect peer
Description

AI-driven drug design company using precision medicine and active learning for small molecule discovery. Exscientia competes directly with Transcripta Bio in AI-enabled biopharma partnerships and pipeline development.

TypeDirect peer
Description

AI + robotics drug discovery platform combining quantum physics, cloud computing, and high-throughput experimentation. XtalPi is a direct peer using AI/ML + wet-lab integration for small molecule discovery.

6Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company leveraging DeepMind's protein structure prediction and broader computational biology capabilities. Isomorphic Labs is an Alphabet-incumbent competitor with substantially greater resources.

TypeDirect peer
Description

AI-driven drug discovery company using human omics data (including transcriptomics) to identify therapeutic targets. Verge's omics-first approach closely mirrors Transcripta's transcriptome-centric strategy.

TypeDirect peer
Description

AI-driven oncology drug discovery and repurposing company using machine learning and genomic data to identify responders. Lantern's drug repurposing focus on approved pharmaceuticals overlaps with Transcripta's indication-expansion approach.

9BPGbio
TypeEmerging player
Description

AI-powered biopharma using multi-omics data (including transcriptomics) and proprietary biological models for drug discovery. BPGbio represents a comparable AI + omics platform emerging player.

TypeEmerging player
Description

AI biology platform leveraging multi-modal patient data for target discovery and drug development. Owkin shares Transcripta's AI + biology thesis but focuses more on federated learning and clinical data than wet-lab perturbation screens.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Transcripta Bio

AI Drug Discovery Platformtranscriptabio.com

Transcripta Bio is a Palo Alto-based biotech using a proprietary Drug-Gene Atlas and Conductor AI to discover and repurpose drugs at transcriptome scale, partnering with biopharma companies, research centers, and patient foundations targeting genetically validated diseases.

What Transcripta Bio does

Transcripta Bio is a privately held, Palo Alto-based biotechnology company building a transcriptome-first drug discovery platform. Its core offering combines a proprietary high-throughput RNA-Seq screening lab (the Discovery Platform), a large proprietary database mapping molecular structure and drug action to whole-cell transcriptomes (the Drug-Gene Atlas, built from over 200 million lab experiments in two years), and a proprietary AI modeling suite called Conductor AI that predicts gene expression directly from the molecular structure of uncharacterized compounds and virtually screens billions of candidates. The platform operates as a closed-loop system: wet-lab results feed the AI, AI predictions are validated in the lab, and the cycle repeats to advance multiple drug programs in parallel. The company focuses on indications where human genetics unequivocally establishes disease causality, and it has reported moving five FDA-approved drugs into single-patient studies for new indications in under two years — a process it characterizes as compressing timelines that would normally take five to eight years.

Transcripta Bio generates revenue through drug discovery partnerships with biopharma companies (structured as licensing and royalty arrangements), supplemented by data monetization via its CRISPR interference dataset distributed through Verily's (Alphabet) Pre precision health platform. Customer segments are primarily biopharma enterprise partners and patient foundations, with academic and clinical researchers reached indirectly via the Verily channel. The company is founder-led (CEO/CSO Chris Moxham, PhD, with Elizabeth Iorns as Scientific Founder & Advisor), venture-backed by JAZZ Venture Partners and BlueYard Capital plus family offices, recognized on the TIME100 Most Influential Companies 2024 list, and headquartered in Palo Alto, California with 11-50 employees.

Transcripta Bio firmographics

Firmographics
Name
Transcripta Bio
Legal name
Transcripta Bio, Inc.
Website
https://transcriptabio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Transcripta Bio is a Palo Alto-based biotech using a proprietary Drug-Gene Atlas and Conductor AI to discover and repurpose drugs at transcriptome scale, partnering with biopharma companies, research centers, and patient foundations targeting genetically validated diseases.
Ownership category
akta.pro rank

Transcripta Bio industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • AI drug discovery
  • Transcriptome analysis
  • RNA-Seq screening
  • Drug-gene mapping
  • Biotech platform

Where Transcripta Bio is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Transcripta Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Discovery Partnerships: Transcripta Bio enters into partnerships with biopharma companies to discover and develop new therapies. The company leverages its platform to identify therapeutic candidates that rebalance gene expression, advancing drug candidates through development in collaboration with partners.
  2. Data Licensing: Transcripta provides CRISPR interference datasets through Verily's Pre platform, enabling researchers to access transcriptomic data for drug discovery research purposes.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Transcripta Bio product offering

Product offering

Core offering

Transcripta Bio operates an integrated AI-powered drug discovery platform that combines high-throughput RNA-Seq wet-lab screening with a proprietary AI modeling suite (Conductor AI) trained on a proprietary transcriptome database (Drug-Gene Atlas). The platform maps molecular structure to whole-cell gene expression to identify therapeutic candidates that rebalance gene expression, with focus on diseases where genetic causality is established.

Product overview

Transcripta Bio is a platform drug development biotechnology company offering an integrated drug discovery ecosystem consisting of the Drug-Gene Atlas (a proprietary transcriptome database), the Discovery Platform (high-throughput RNA-Seq screening), and Conductor AI (predictive modeling suite). These three components work together in a closed-loop system: wet lab results from the Discovery Platform feed into Conductor AI, which virtually screens billions of compounds to predict therapeutic candidates, with findings validated back in the lab. The platform focuses on diseases where causality is established by human genetics, using small molecules to rebalance gene expression.

Differentiator

Problem solved

Functional benefit

Brands

  • Conductor AI: Proprietary AI modeling suite that predicts gene expression directly from molecular structure of compounds, trained on Transcripta's Drug-Gene Atlas dataset.
  • Drug-Gene Atlas

Quantifiable outcome

  • Reduced drug discovery timelines from years/months to months/weeks
  • +3 more outcomes

Companies that use Transcripta Bio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Transcripta Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Transcripta Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Verily (Alphabet)coreTechnology or Integration · 18 February 2026Transcripta Bio provides CRISPR interference dataset mapping gene knockdowns linked to rare diseases as part of Verily's Pre precision health platform. This integration enables researchers to access Transcripta's transcriptomic data through Verily's self-serve platform.
  • Leading Biopharma CompaniescoreStrategic or Co-development Partner · 16 April 2025Transcripta Bio is partnering with leading biopharma companies to uncover and advance new drug discovery opportunities, leveraging the company's transcriptome-based AI platform and Drug-Gene Atlas database.
  • Research CentersmajorStrategic or Co-development Partner · 16 April 2025Transcripta Bio partners with research centers to advance drug discovery using their high-throughput screening platform and AI capabilities.
  • Patient FoundationsmajorStrategic or Co-development Partner · 16 April 2025Transcripta Bio partners with patient foundations to uncover and advance new therapeutic opportunities, with particular focus on rare diseases where genetic causality is established.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Transcripta Bio competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning. Recursion operates a similar 'closed-loop' model and is a leading direct competitor in the AI-enabled small molecule discovery space.
  • Insitro: Machine learning-driven drug discovery platform using high-throughput biology and proprietary data generation. Insitro is a direct competitor pursuing AI-enabled small molecule discovery with biopharma partnerships.
  • Schrödinger, Inc. Computational chemistry and molecular simulation platform used for drug discovery across biopharma. Schrödinger is a direct competitor offering AI/ML-driven virtual screening and small molecule design tools.
  • Exscientia: AI-driven drug design company using precision medicine and active learning for small molecule discovery. Exscientia competes directly with Transcripta Bio in AI-enabled biopharma partnerships and pipeline development.
  • XtalPi: AI + robotics drug discovery platform combining quantum physics, cloud computing, and high-throughput experimentation. XtalPi is a direct peer using AI/ML + wet-lab integration for small molecule discovery.
  • Verge Genomics: AI-driven drug discovery company using human omics data (including transcriptomics) to identify therapeutic targets. Verge's omics-first approach closely mirrors Transcripta's transcriptome-centric strategy.
  • Lantern Pharma: AI-driven oncology drug discovery and repurposing company using machine learning and genomic data to identify responders. Lantern's drug repurposing focus on approved pharmaceuticals overlaps with Transcripta's indication-expansion approach.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's protein structure prediction and broader computational biology capabilities. Isomorphic Labs is an Alphabet-incumbent competitor with substantially greater resources.

Emerging players

  • BPGbio: AI-powered biopharma using multi-omics data (including transcriptomics) and proprietary biological models for drug discovery. BPGbio represents a comparable AI + omics platform emerging player.
  • Owkin: AI biology platform leveraging multi-modal patient data for target discovery and drug development. Owkin shares Transcripta's AI + biology thesis but focuses more on federated learning and clinical data than wet-lab perturbation screens.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Transcripta Bio social profiles

Digital presence

Transcripta Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Transcripta Bio leadership team

Management profile

Number of profiles

Profiles2 records

Transcripta Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Transcripta Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transcripta Bio

What does Transcripta Bio do?

Transcripta Bio operates an integrated AI-powered drug discovery platform that combines high-throughput RNA-Seq wet-lab screening with a proprietary AI modeling suite (Conductor AI) trained on a proprietary transcriptome database (Drug-Gene Atlas). The platform maps molecular structure to whole-cell gene expression to identify therapeutic candidates that rebalance gene expression, with focus on diseases where genetic causality is established.

Is Transcripta Bio a public or private company?

Transcripta Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Transcripta Bio founded?

Transcripta Bio was founded in 2023. It employs 11 to 50 people.

Where is Transcripta Bio based?

Transcripta Bio is headquartered in Palo Alto, United States, in the North America region.

How does Transcripta Bio make money?

Two revenue lines are on record. Drug Discovery Partnerships are the primary driver. The others are data Licensing.

Who are Transcripta Bio's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Inc., Exscientia, XtalPi, Verge Genomics and Lantern Pharma. Isomorphic Labs is listed as a broad incumbent. Emerging players are BPGbio and Owkin.

Does Transcripta Bio have an API?

No public API is recorded for Transcripta Bio.

What industry is Transcripta Bio in?

Transcripta Bio's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageTranscripta Bio Announces Research Collaboration to Advance Discovery of New Treatments for Autism Spectrum DisorderTranscripta Bio announced a know-how agreement with Mayo Clinic to combine clinical genomics and transcriptomic drug discovery for autism spectrum disorder. The collaboration will characterize transcriptomic subtypes of ASD using whole-genome and RNA sequencing. Mayo Clinic has a financial interest in the technology.YahooTranscripta Bio, Mayo Clinic join force on ALS therapiesTranscripta Bio and Mayo Clinic signed a research collaboration and licensing agreement to identify ALS treatments. The initiative creates a patient-derived molecular map using single-cell RNA sequencing on donated tissue. The work aims to generate findings that could inform patient care and accelerate targeted therapies.YahooTranscripta Bio, Mayo Clinic join force on ALS therapiesTranscripta Bio and Mayo Clinic signed a research collaboration and licensing agreement to identify ALS treatments. The initiative creates a patient-derived molecular map using single-cell RNA sequencing on donated tissue. The work aims to generate disease profiles and nominate new drug candidates.Pharmaceutical TechnologyTranscripta Bio, Mayo Clinic join force on ALS therapiesTranscripta Bio and Mayo Clinic signed a research collaboration and licensing agreement to identify ALS treatments. Mayo Clinic will recruit living ALS patients for single-cell RNA sequencing, and Transcripta Bio will use its transcriptomic platform to nominate drug candidates. The work aims to inform patient care and accelerate targeted therapies.EIN PresswireTranscripta Bio, Mayo Clinic join force on ALS therapiesTranscripta Bio and Mayo Clinic signed a research collaboration and licensing agreement to identify ALS treatments. The initiative creates a patient-derived molecular map using single-cell RNA sequencing on donated tissue. The work aims to generate findings that could inform patient care and accelerate targeted therapies.Business Wire BlogTranscripta Bio Announces Research Collaboration to Advance Discovery of New ALS TreatmentsTranscripta Bio announced a research collaboration and licensing agreement with Mayo Clinic to advance ALS treatment discovery. The partnership will use single-cell RNA sequencing on donated tissue to build patient-derived ALS disease signatures and nominate novel therapeutic targets. Mayo Clinic is prospectively enrolling living ALS patients under an IRB-approved protocol.Business Wire BlogTranscripta Bio & Synfini Collaborate to Identify a Lead Candidate Against a Key Driver of Huntington’s Disease Progression in a Matter of WeeksTranscripta Bio and Synfini announced a validated lead candidate against MSH3, a gene driving Huntington's disease progression, in weeks. The collaboration compressed the discovery cycle from the industry standard of 12-18 months. Huntington's disease affects 41,000 symptomatic Americans, with no approved therapy.citybizTranscripta Bio Expands Scientific Advisory Board as Four Drug Programs AdvanceTranscripta Bio expanded its Scientific Advisory Board with experts in genetics, transcriptomics, and clinical development as it advances four neurological and neuromuscular programs. The company targets clinical trial initiation for its autism and FSHD programs in 2027, using its closed-loop drug discovery platform to prioritize candidates.AInvestN-of-1 Was Never the BusinessTranscripta Bio has secured $24 million in funding to transition from a custom N-of-1 treatment service to a clinical-stage drug developer, launching IND-enabling studies for autism and facioscapulohumeral muscular dystrophy. The company utilizes AI-driven screening of existing drugs against patient-specific genetic profiles, leveraging data from rare disease cases to identify broader therapeutic opportunities. This strategic shift aims to validate its approach through formal clinical trials rather than relying solely on anecdotal evidence from individual patients.AllsciTranscripta Bio Raises $24M for AI Drug DiscoveryCalifornia-based Transcripta Bio has raised USD 24 million in follow-on funding to its Series A round, bringing total disclosed funding to roughly USD 34 million, with new investors Mayo Clinic and Omnimed joining existing backers JAZZ Venture Partners and BlueYard Capital. The capital will be used to complete IND-enabling studies and prepare for clinical trials in autism spectrum disorder (ASD) and facioscapulohumeral muscular dystrophy (FSHD). The company has also formed a May 2025 research collaboration with Microsoft Research to expand its AI-driven gene discovery work, which uses transcriptomic signature matching to identify compounds for neurological and neuromuscular diseases.